Zealand Pharma

Director's Dealing • Nov 16, 2015

Copenhagen, 2015-11-16 17:38 CET (GLOBE NEWSWIRE) -- 16 November 2015 –
Pursuant to the Danish Securities Trading Act, section 28a, Zealand must
disclose information on transactions with the company’s shares and related
securities by executives and persons/companies closely related to them.

With reference to the above, Zealand announces it has received information on
the following transactions for disclosure:

Name: Christian Thorkildsen

Reason: Employee elected member of the Board of Directors

Issuer: Zealand Pharma A/S

Designation: Shares

ISIN Code: DK0060257814

Transaction: Exercise of warrants

Trading Date: 13 November 2015

Market: Nasdaq Copenhagen

Number: 27,000

Price: DKK 77.00

Total value: DKK 2,079,000.00

Name: Helle Størum

Reason: Employee elected member of the Board of Directors

Issuer: Zealand Pharma A/S

Designation: Shares

ISIN Code: DK0060257814

Transaction: Exercise of warrants

Trading Date: 13 November 2015

Market: Nasdaq Copenhagen

Number: 7,500

Price: DKK 77.00

Total value: DKK 577,500.00

Name: Jens Peter Stenvang

Reason: Employee elected member of the Board of Directors

Issuer: Zealand Pharma A/S

Designation: Shares

ISIN Code: DK0060257814

Transaction: Exercise of warrants

Trading Date: 13 November 2015

Market: Nasdaq Copenhagen

Number: 5,000

Price: DKK 77.00

Total value: DKK 385,000.00

                                  ?????

For further information, please contact:

Hanne Leth Hillman, Senior Vice President for Investor Relations and
Communications

Tel: +45 50 60 36 89, email: hlh@zealandpharma.com

About Zealand Pharma

Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (“Zealand”) is a biotech company
with leading-edge scientific expertise in turning peptides into medicines.
Zealand has a growing proprietary pipeline of novel specialty drug candidates
and a mature portfolio of products and projects under license collaborations
with Sanofi, Helsinn Healthcare and Boehringer Ingelheim.

Zealand’s first invented medicine, lixisenatide, a once-daily prandial GLP-1
analogue for the treatment of Type 2 diabetes, is marketed globally outside the
US as Lyxumia® by Sanofi and under regulatory review in the US. The license
collaboration with Sanofi covers also a single-product combination of
lixisenatide and insulin glargine (Lantus®) which is on track for regulatory
submission in the US in Q4 2015 and in the European Union in Q1 2016.

The proprietary pipeline includes; danegaptide for ischemic reperfusion
Injuries in Phase II development; ZP1848 for Short Bowel Syndrome in Phase II
development; and the stable glucagon analogue, ZP4207, in Phase II preparation
both as a single-dose rescue pen for severe hypoglycemia and for multiple-dose
use to treat and control mild to moderate hypoglycemia; as well as several
preclinical peptide therapeutics.

The company is based in Copenhagen (Glostrup), Denmark. For further information
about Zealand’s business and activities, please visit: www,zealandpharma.com or
follow us on Twitter @ZealandPharma